Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
AYTU BIOPHARMA, INC.
AI Executive Summary
AI-powered analysis of 8-K filing content
Aytu BioPharma and Lannett Company mutually terminated their exclusive Metadate license agreement effective immediately on June 23, 2026. While this removes a product from Aytu's exclusive distribution rights, the company retains the ability to sell existing inventory, representing a strategic realignment that could impact revenue and product portfolio composition.
Key Takeaways
Mutual termination of the Metadate exclusive license agreement originally signed May 11, 2022, with amendments in July 2023 and July 2025
Termination is effective immediately with certain provisions surviving per the Termination Agreement
2 more takeaways